机构:[1]Kunming Med Univ, Affiliated Hosp 1, Dept Urol, Kunming 650032, Yunnan, Peoples R China外科科室泌尿外科泌尿外一科[2]Yunnan Univ Chinese Med, Dept Pathol, Kunming 650504, Yunnan, Peoples R China[3]Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China[4]Kunming Med Univ, Biomed Engn Res Ctr, Kunming 650500, Yunnan, Peoples R China[5]Yunnan Univ Chinese Med, Sch Chinese Mat Med, Kunming 650500, Yunnan, Peoples R China[6]Yunnan Univ Chinese Med, Yunnan Key Lab Southern Med Utilizat, Kunming 650500, Yunnan, Peoples R China
The epidermal growth factor receptor (EGFR) is a promising therapeutic target in bladder cancer (BC). Thus, the development of novel EGFR inhibitor is urgently needed. We computationally screened 3,167 worldwide approved small molecule drugs for potential wild-type EGFR inhibitors. The antibiotic and antiprotozoal agent dibromopropamidine dihydrochloride exhibited the highest cytotoxic activity in a dose- and time-dependent manner, with the IC50 similar to that reported for the FDA approved EGFR inhibitors, gefitinib and higher than afatinib. We demonstrated that dibromopropamidine dihydrochloride inhibited the wild type EGFR kinase activity while had no effect on HER-2 kinase activity. Furthermore, dibromopropamidine dihydrochloride treatment significantly promoted cell apoptosis and inhibited the phosphorylation of EGFR and its downstream proteins AKT and ERK in a dose-dependent manner. Structural analysis of the predicted binding conformation suggested that dibromopropamidine dihydrochloride binds to EGFR at ATP binding site via the formation of two hydrogen bonds with GLY796 and ASP855. Finally, dibromopropamidine dihydrochloride significantly suppressed tumor growth in vivo. These results suggest for the first time that dibromopropamidine dihydrochloride is an EGFR inhibitor, and a promising anticancer candidate drug for the treatment of BC.
基金:
Scientific Research Fund project of Department of Education of Yunnan Province [2018JS208]; Guizhou Science & Technology Department [QKHJC(2017)1171]; Yunnan Applied Basic Res. of Combined Foundation of Yunnan Province Science & Technology Dept, Yunnan Univ. of Chinese Medicine [2018FF001(-026), 2019FF002(-050,-040)]; Yunnan Province Science and Technology Department-Kunming Medical University Joint Fund for Fundamental Research [2019FE001 (-064)]; National Natural Science Foundation of China [82060862, 81960133, 81960666]; program Innovative Research Team in Science and Technology in Yunnan Province [202005AE160004]; [YNWR-YLXZ-2019-019]
第一作者机构:[1]Kunming Med Univ, Affiliated Hosp 1, Dept Urol, Kunming 650032, Yunnan, Peoples R China[4]Kunming Med Univ, Biomed Engn Res Ctr, Kunming 650500, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Kunming Med Univ, Affiliated Hosp 1, Dept Urol, Kunming 650032, Yunnan, Peoples R China[*1]Kunming Med Univ, Affiliated Hosp 1, Dept Urol, Kunming 650032, Yunnan, Peoples R China[2]Yunnan Univ Chinese Med, Dept Pathol, Kunming 650504, Yunnan, Peoples R China[*2]Yunnan Univ Chinese Med, Dept Pathol, Kunming 650504, Yunnan, Peoples R China
推荐引用方式(GB/T 7714):
Ke Kunbin,Gu Peng,Chen Yin,et al.The Antibiotic and Antiprotozoal Agent Dibromopropamidine Dihydrochloride is a New EGFR Inhibitor and Potential Anticancer Drug for Bladder Cancer[J].CHEMISTRYSELECT.2022,7(9):e202200424.doi:10.1002/slct.202200424.
APA:
Ke, Kunbin,Gu, Peng,Chen, Yin,Li, Hongjian,Shen, Zhengchao...&Shi, Xinan.(2022).The Antibiotic and Antiprotozoal Agent Dibromopropamidine Dihydrochloride is a New EGFR Inhibitor and Potential Anticancer Drug for Bladder Cancer.CHEMISTRYSELECT,7,(9)
MLA:
Ke, Kunbin,et al."The Antibiotic and Antiprotozoal Agent Dibromopropamidine Dihydrochloride is a New EGFR Inhibitor and Potential Anticancer Drug for Bladder Cancer".CHEMISTRYSELECT 7..9(2022)